KBC Group Increases Stake in Eli Lilly by 1.8%

Belgian financial group now owns over $750 million in Lilly shares

Apr. 19, 2026 at 9:04am

Got story updates? Submit your updates here. ›

An extreme close-up of the intricate gears and mechanisms of a high-tech pharmaceutical manufacturing machine, rendered in a heavy industrial style with a sense of scale and complexity.The sophisticated machinery and infrastructure behind Eli Lilly's pharmaceutical innovations reflect the company's technological prowess and manufacturing capabilities.Indianapolis Today

KBC Group NV, a major Belgian financial services group, has increased its stake in pharmaceutical giant Eli Lilly and Company by 1.8% in the fourth quarter, according to a recent SEC filing. KBC Group now owns 704,017 shares of Lilly's stock, worth approximately $756.6 million, making it one of the company's largest institutional investors.

Why it matters

Eli Lilly is one of the world's leading pharmaceutical companies, known for its innovative drugs and therapies. KBC Group's increased investment signals confidence in Lilly's long-term growth potential and the strength of its product pipeline. This news also highlights the continued interest from major institutional investors in the pharmaceutical sector.

The details

According to the 13F filing, KBC Group acquired an additional 12,127 shares of Eli Lilly in the fourth quarter, bringing its total stake to 704,017 shares. This represents approximately 0.07% of Lilly's outstanding shares and makes KBC Group the company's 9th largest institutional investor. The increased investment comes as Lilly has seen its stock price rise significantly in recent years, driven by the success of key drugs like Trulicity, Taltz, and Verzenio.

  • KBC Group filed its 13F report for the fourth quarter of 2025 on April 19, 2026.

The players

KBC Group NV

A major Belgian financial services group that owns a $756.6 million stake in Eli Lilly and Company, making it one of the pharmaceutical company's largest institutional investors.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana, known for its innovative drugs and therapies in areas like diabetes, immunology, and oncology.

Got photos? Submit your photos here. ›

The takeaway

KBC Group's increased investment in Eli Lilly underscores the continued appeal of the pharmaceutical sector for major institutional investors. As Lilly continues to develop new drugs and expand its global reach, its stock remains an attractive long-term holding for large financial firms like KBC Group.